U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H30N3O8.Cl
Molecular Weight 535.974
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERDEXMETHYLPHENIDATE CHLORIDE

SMILES

[Cl-].[H][C@@]1(CCCCN1C(=O)OC[N+]2=CC=CC(=C2)C(=O)N[C@@H](CO)C(O)=O)[C@H](C(=O)OC)C3=CC=CC=C3

InChI

InChIKey=GONQEUJYYMYNMN-HWAJWLCKSA-N
InChI=1S/C25H29N3O8.ClH/c1-35-24(33)21(17-8-3-2-4-9-17)20-11-5-6-13-28(20)25(34)36-16-27-12-7-10-18(14-27)22(30)26-19(15-29)23(31)32;/h2-4,7-10,12,14,19-21,29H,5-6,11,13,15-16H2,1H3,(H-,26,30,31,32);1H/t19-,20+,21+;/m0./s1

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C25H29N3O8
Molecular Weight 499.5131
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Dexmethylphenidate is the dextrorotary form of methylphenidate. Dexmethylphenidate is marketed under the trade name Focalin. Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threoenantiomers. Focalin is a central nervous system (CNS) stimulant, available in three tablet strengths. Each tablet contains dexmethylphenidate hydrochloride 2.5, 5, or 10 mg for oral administration. Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment. Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.

CNS Activity

CNS Active
3913
Curator's Comment: Dexmethylphenidate is a central nervous system (CNS) stimulant

Originator

Approval Year

2001
194
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 161.0 nM [Ki]
Inhibitor
8297
 206.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
FOCALIN

Approved Use

Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD.

Launch Date

1.00560962E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
23.72 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
22.13 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
10.7 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28590363
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
120.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
131.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
79.8 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28590363
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.68 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.81 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28590363
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Other AEs: Vomiting, Agitation...
Other AEs:
Vomiting
Agitation
Tremor
Hyperreflexia
Muscle twitching
Convulsions
Euphoria
Confusion
Hallucinations
Delirium
Sweating
Flushing
Headache
Hyperpyrexia
Tachycardia
Palpitations
Cardiac arrhythmias
Hypertension
Mydriasis
Mucosal dryness
Rhabdomyolysis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
Disc. AE: Twitching, Anorexia...
AEs leading to
discontinuation/dose reduction:
Twitching (1%)
Anorexia (1%)
Insomnia (1%)
Tachycardia (1%)
Insomnia (1.8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Disc. AE: Cardiac disorders, Stroke...
Other AEs: Increased blood pressure, Heart rate increased...
AEs leading to
discontinuation/dose reduction:
Cardiac disorders (grade 3-5)
Stroke (grade 3-5)
Myocardial infarction (grade 3-5)
Seizures
Raynaud's phenomenon
Other AEs:
Increased blood pressure
Heart rate increased
Psychotic symptom (grade 3-5)
Psychotic symptom
Manic symptom
Aggression
Growth suppression
Priapism
Erection prolonged
Vascular disorders
Visual disturbance
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.8
Disc. AE: Feeling jittery, Anorexia...
AEs leading to
discontinuation/dose reduction:
Feeling jittery (1.8%)
Anorexia (1.2%)
Anxiety (1.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.8
AEs

AEs

AESignificanceDosePopulation
Agitation
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Cardiac arrhythmias
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Confusion
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Convulsions
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Delirium
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Euphoria
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Flushing
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Hallucinations
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Headache
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Hyperpyrexia
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Hyperreflexia
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Hypertension
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Mucosal dryness
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Muscle twitching
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Mydriasis
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Palpitations
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Rhabdomyolysis
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Sweating
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Tachycardia
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Tremor
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Vomiting
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.11
Anorexia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
Insomnia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
Tachycardia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
Twitching 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
Insomnia 1.8%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.7
Aggression
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Erection prolonged
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Growth suppression
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Heart rate increased
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Increased blood pressure
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Manic symptom
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Priapism
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Psychotic symptom
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Vascular disorders
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Visual disturbance
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Raynaud's phenomenon Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Seizures Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Psychotic symptom grade 3-5
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Cardiac disorders grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Myocardial infarction grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Stroke grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.1
Anorexia 1.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.8
Anxiety 1.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.8
Feeling jittery 1.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Page: p.8
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2C8
911

CYP2C19
1478

CYP2E1
882

CYP3A
214
esterase
72

CES2
28

P-gp
1537
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP2C19
1553
 no
CYP2C8
965
 no
CYP2C9
1819
 no
CYP2E1
970
 no
CYP3A
298
 no
CYP2D6
1891
 no
no (co-administration study)
Comment: Clinically, methylphenidate coadministration did not increase plasma concentrations of the CYP2D6 substrate desipramine.
Page: 11.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES2
28
 no
P-gp
1537
 weak
esterase
72
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:51860
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51860
ZINC
ZINC000000896711
http://zinc15.docking.org/substances/ZINC000000896711
PubMed

PubMed

TitleDatePubMed
[Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
2001 Sep-Oct
The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.
2002
Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
2002
Dexmethylphenidate.
2002
Dexmethylphenidate (Focalin) for ADHD.
2002 May 13
Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats.
2003 Feb
D-Methylphenidate is non-genotoxic in in vitro and in vivo assays.
2003 May 9
A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.
2004 Feb
A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
2004 Nov
Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
2004 Sep 30
Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.
2004 Winter
A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
2004 Winter
Attention deficit/hyperactivity disorder: pharmacotherapy.
2005 Jan
Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
2005 Jul
Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core.
2005 Mar
ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine.
2006
Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
2006
A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
2006 Dec 20
[Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].
2006 Jan
Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
2006 Jul
Misuse of "study drugs:" prevalence, consequences, and implications for policy.
2006 Jun 9
Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration.
2006 Oct
[Pharmacotherapy of adult Attention Deficit/Hyperactivity Disorder (ADHD): a systematic review].
2007
The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities.
2007 Aug
Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
2007 Dec
Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
2007 Jun 15
Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate.
2007 May 31
Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence.
2007 Nov 15
The nonmedical use of prescription ADHD medications: results from a national Internet panel.
2007 Oct 31
A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
2008
Treatment of adult ADHD: is current knowledge useful to clinicians?
2008 Feb
Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
2008 Jun
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
2008 May
Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for management.
2008 Sep
Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.
2009
Once-daily medications for the pharmacological management of ADHD in adults.
2009 Apr
Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
2009 Dec
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer.
2009 Jun 29
A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD).
2009 Jun 8
Pharmacotherapy for adult ADHD.
2009 May
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
2009 Nov
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
2010
Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects.
2010 Apr
Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder.
2010 Aug
Use of psychostimulants in patients with dementia.
2010 Oct
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.
2010 Sep 3
Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.
2011 Jan 1
Patents

Patents

JP2009526755A
447
JP2011510954A
143

Sample Use Guides

In Vivo Use Guide
Focalin (Dexmethylphenidate) is administered twice daily, at least 4 hours apart. Focalin may be administered with or without food. The recommended starting dose of Focalin for patients who are not currently taking racemic methylphenidate, or for patients who are on stimulants other than methylphenidate, is 5 mg/day (2.5 mg twice daily). Dosage may be adjusted in 2.5 to 5 mg increments to a maximum of 20 mg/day (10 mg twice daily). In general, dosage adjustments may proceed at approximately weekly intervals.
Route of Administration: Oral
In Vitro Use Guide
Dexmethylphenidate inhibition [3H]dopamine uptake at human DAT expressed in mouse N2A cells with IC50 156 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 13:44:30 UTC 2023
Edited
by admin
on Sat Dec 16 13:44:30 UTC 2023
Record UNII
FN54BT298Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERDEXMETHYLPHENIDATE CHLORIDE
USAN  
Official Name English
SERDEXMETHYLPHENIDATE CHLORIDE [ORANGE BOOK]
Common Name English
SERDEXMETHYLPHENIDATE CHLORIDE COMPONENT OF AZSTARYS
Brand Name English
SERDEXMETHYLPHENIDATE CHLORIDE [USAN]
Common Name English
PYRIDINIUM, 3-((((1S)-1-CARBOXY-2-HYDROXYETHYL)AMINO)CARBONYL)-1-(((((2R)-2-((1R)-2-METHOXY-2-OXO-1-PHENYLETHYL)-1-PIPERIDINYL)CARBONYL)OXY)METHYL)-, CHLORIDE (1:1)
Systematic Name English
Serdexmethylphenidate chloride [WHO-DD]
Common Name English
KP415 CL
Code English
AZSTARYS COMPONENT SERDEXMETHYLPHENIDATE CHLORIDE
Brand Name English
Code System Code Type Description
RXCUI
2562177
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
EPA CompTox
DTXSID901336633
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
PUBCHEM
134823897
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
SMS_ID
300000005364
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
DAILYMED
FN54BT298Y
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
CAS
1996626-30-2
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
USAN
EF-151
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
FDA UNII
FN54BT298Y
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
NCI_THESAURUS
C170377
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
WIKIPEDIA
Serdexmethylphenidate
Created by admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
PRIMARY
Related Record Type Details
Structure of SERDEXMETHYLPHENIDATE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of DEXMETHYLPHENIDATE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966